These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36650015)

  • 21. Patents as a Driver of the Unprecedented Biomedical Response to COVID-19.
    Mossoff A; Adalja A
    Inquiry; 2022; 59():469580221124819. PubMed ID: 36129280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVAX, vaccine donations and the politics of global vaccine inequity.
    de Bengy Puyvallée A; Storeng KT
    Global Health; 2022 Mar; 18(1):26. PubMed ID: 35248116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19.
    Yu H
    Inquiry; 2021; 58():469580211059734. PubMed ID: 34855535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity.
    Wimmer S; Keestra SM
    Int J Health Policy Manag; 2022 May; 11(5):567-578. PubMed ID: 32945638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.
    Bright B; Babalola CP; Sam-Agudu NA; Onyeaghala AA; Olatunji A; Aduh U; Sobande PO; Crowell TA; Tebeje YK; Phillip S; Ndembi N; Folayan MO
    Global Health; 2021 Mar; 17(1):24. PubMed ID: 33658050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.
    Kohler J; Wong A; Tailor L
    Health Hum Rights; 2022 Dec; 24(2):159-175. PubMed ID: 36579316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability.
    Moon S; Armstrong J; Hutler B; Upshur R; Katz R; Atuire C; Bhan A; Emanuel E; Faden R; Ghimire P; Greco D; Ho CW; Kochhar S; Schaefer GO; Shamsi-Gooshki E; Singh JA; Smith MJ; Wolff J
    Lancet; 2022 Jan; 399(10323):487-494. PubMed ID: 34902308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hard choices: Ethical challenges in phase 1 of COVID-19 vaccine roll-out in South Africa.
    Moodley K; Blockman M; Pienaar D; Hawkridge AJ; Meintjes J; Davies MA; London L
    S Afr Med J; 2021 Mar; 111(6):554-558. PubMed ID: 34382565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed Access to COVID-19 Vaccines: A Perspective on Low-income Countries in Africa.
    Hassan MA; Aliyu S
    Int J Health Serv; 2022 Jul; 52(3):323-329. PubMed ID: 35469499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attributes of national governance for an effective response to public health emergencies: Lessons from the response to the COVID-19 pandemic.
    Assefa Y; Woldeyohannes S; Cullerton K; Gilks CF; Reid S; Van Damme W
    J Glob Health; 2022 Jul; 12():05021. PubMed ID: 35787525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap.
    Borges LC; Zeferino de Menezes H; Crosbie E
    Int J Health Policy Manag; 2022 Dec; 11(12):3101-3113. PubMed ID: 36028975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access to COVID-19 Vaccines: A New Global Approach.
    Bouderhem R
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Public health ethics and the COVID-19 pandemic.
    Aliyu AA
    Ann Afr Med; 2021; 20(3):157-163. PubMed ID: 34558443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study.
    Lalani HS; Nagar S; Sarpatwari A; Barenie RE; Avorn J; Rome BN; Kesselheim AS
    BMJ; 2023 Mar; 380():e073747. PubMed ID: 36858453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving pandemic preparedness through better, faster influenza vaccines.
    Newland M; Durham D; Asher J; Treanor JJ; Seals J; Donis RO; Johnson RA
    Expert Rev Vaccines; 2021 Mar; 20(3):235-242. PubMed ID: 33576708
    [No Abstract]   [Full Text] [Related]  

  • 37. Public health and social measures to mitigate the health and economic impact of the COVID-19 pandemic in Turkey, Egypt, Ukraine, Kazakhstan, and Poland during 2020-2021: situational analysis.
    Kitamura N; Abbas K; Nathwani D
    BMC Public Health; 2022 May; 22(1):991. PubMed ID: 35578330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world?
    Dionisio D; Gass R; McDermott P; Racalbuto V; Madeo M; Braghieri G; Crowley S; Pinheiro Edos S; Graaff P; Vasan A; Eksaengsri A; Moller H; Khanna AK; Kraisintu K; Juneja S; Nicolaou S; Sengupta A; Esperti F; Messeri D
    Curr HIV Res; 2007 Mar; 5(2):155-87. PubMed ID: 17346132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. European collaborations on medicine and vaccine procurement.
    Vogler S; Haasis MA; van den Ham R; Humbert T; Garner S; Suleman F
    Bull World Health Organ; 2021 Oct; 99(10):715-721. PubMed ID: 34621089
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.